4,8-dimethyl-1-oxa-4,8-diaza-spiro[4.5]decane | 23008-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4,8-dimethyl-1-oxa-4,8-diaza-spiro[4.5]decane
• 英文别名: 4,8-Dimethyl-1-oxa-4,8-diazaspiro[4.5]decane
• CAS: 23008-83-5
• 化学式: C₉H₁₈N₂O
• 分子量: 170.255
• InChiKey: WBICVBZIEVRHIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 N-甲基-2-羟基乙胺 以 苯 为溶剂， 反应 2.0h， 生成 4,8-dimethyl-1-oxa-4,8-diaza-spiro[4.5]decane
  参考文献：
  名称：

  新化合物：恶唑烷和衍生的氨基醇。

  摘要：

  DOI：

  10.1002/jps.2600580429

文献信息

• ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT
  申请人：WANG HOAU-YAN

  公开号：US20140017698A1

  公开（公告）日：2014-01-16

  An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ 42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7 - 12 . An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.
• METHOD FOR INHIBITING GROWTH OF CANCER CELLS
  申请人：Pain Therapeutics, Inc.

  公开号：US20150148318A1

  公开（公告）日：2015-05-28

  A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 μM concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19 - 24.
• US9354223B2
  申请人：——

  公开号：US9354223B2

  公开（公告）日：2016-05-31
• US9340558B2
  申请人：——

  公开号：US9340558B2

  公开（公告）日：2016-05-17
• US9433604B2
  申请人：——

  公开号：US9433604B2

  公开（公告）日：2016-09-06